胸腺肽α_1联合干扰素α-1b、利巴韦林治疗老年慢性丙型肝炎患者的临床观察  

Efficiency of thymosin α_1 comblined interferon α-1b with Ribavirin in the treatment of elderly patients with chronic hepatitis C

作　　者：崔琨[1,2] 范公忍[2] 熊锦华[2] 姬胜杰 侯保全 龚新惠 李怡卓 高慧 钟芳 

机构地区：[1]河南省商丘市长征人民医院肝病科,河南商丘476000 [2]北京军区总医院全军肝病治疗中心,北京100700

出　　处：《中国医药导报》2012年第24期80-82,共3页China Medical Herald

摘　　要：目的观察胸腺肽α1联合干扰素α-1b、利巴韦林治疗老年慢性丙型肝炎患者的治疗效果和安全性。方法将72例老年慢性丙型肝炎患者分为A组和B组,A组42例给予胸腺肽α1联合干扰素α-1b 40μg和利巴韦林胶囊;B组30例给予干扰素α-1b 40μg和利巴韦林胶囊,两组均治疗48周,随访24周。结果 A组患者治疗结束时应答率为59.0%,高于B组(46.4%):随访24周A组患者复发率为7.7%,明显低于B组(14.3%),差异有统计学意义(P<0.05或P<0.01);A组对药物具有较好的耐受性,其不良反应发生率明显低于B组(P<0.05或P<0.01)。结论胸腺肽α1联合干扰素α-1b、利巴韦林治疗老年慢性丙型肝炎具有较好的治疗效果,且副作用较轻。Objective To evaluate the safety and effect of thymoison α1 combined interferon α-1b with Ribavirin as antiviral therapy for the elderly patients with chronic hepatitis C.Methods 72 patients with chronic hepatitis C virus（HCV） were divided into group A and B;42 patients were given thymoison α1 combined interferon α-1b and Ribavirin in group A,30 patients were given thymoison α1 combined interferon α-1b as control group,all patients were treated for 48 weeks and followed up for 24 weeks after treatment.Results At the end of treatment,the ETVR was 59.0% in group A,which was higher than that of group B（46.4%）.Following up studies were conducted,the recurrence rate was 7.7% in group A,which was lower than that of group B（14.3%）,there were statistically significant differences（P 0.05 or P 0.01）.Having a good tolerance,the incidence of adverse reactions in group A was significantly lower than group B（P 0.05 or P 0.01）.Conclusion Thymoison α1 combined interferon α-1b with Ribavirin in the treatment of elderly patients with chronic hepatitis C virus can increase the effects and decrease the side effects.

关 键 词：慢性丙型肝炎 干扰素Α-1B 利巴韦林 胸腺肽α1 老年 

分 类 号：R575.2[医药卫生—消化系统]